Evidence map›Paper›PMID 41818608›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Biomimetic Cell Membrane-Coated MOFs System for Targeted Cancer Therapy.

Qilu Wu, Jia Song Deon Chon, Yuxiao Feng, Kang Liang, Shiming Li, Can Yang Zhang, Jun Ge

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qilu WuKey Lab for Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing, China.
Jia Song Deon ChonKey Lab for Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing, China.
Yuxiao FengKey Lab for Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing, China.
Kang LiangSchool of Chemical Engineering, The University of New South Wales, Sydney, NSW, Australia.
Shiming LiBeijing Tongren Eye Center, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Can Yang ZhangInstitute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.ORCID https://orcid.org/0000-0002-6975-5781
Jun GeKey Lab for Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing, China.

Funding

Beijing Natural Science Foundation L248023Beijing Natural Science Foundation Z240030National Key R&D Program of China 2023YFA0913600National Natural Science Foundation of China 22278242National Natural Science Foundation of China 22425803Pearl River Talent Program 2021QN02Y225Shenzhen International Graduate School at Tsinghua University HW2023009Shenzhen International Graduate School at Tsinghua University JC2021011Shenzhen Science and Technology Program KCXFZ20230731094459001Shenzhen Science and Technology Program KCXFZ20240903093102004Tsinghua University Initiative Research Program 2023Z02ORD001
6 · The paper itself

Abstract

The integration of metal-organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine. In this review, we systematically summarized recent advances in cell membrane-camouflaged MOF as drug delivery systems, focusing on their unique advantages in tumor targeting, immune evasion, and biocompatibility. By emulating the characteristics of natural cells, these biomimetic systems demonstrate enhanced circulation time, increased accumulation within tumors, and decreased uptake by macrophages. A critical analysis was conducted on a variety of membrane sources, including cancer cells, red blood cells, and macrophages. The analysis focused on the functionalities of these sources in tumor homing and immune modulation. The following design strategies are of particular interest: hybrid membrane engineering and stimuli-responsive drug release mechanisms. This field demonstrates considerable potential for combination therapies integrating chemotherapy, immunotherapy, and photothermal modalities. In the future, the development of new drugs should prioritize intelligent drug release systems and personalized treatment through advanced biomaterial engineering.

Indexed as

Biomimetic MaterialsBiomimeticsCell MembraneDrug Delivery SystemsMetal-Organic FrameworksNanomedicineNeoplasmsAnimalsAntineoplastic AgentsHumansAntineoplastic AgentsMetal-Organic Frameworksbiomimiccancer therapycell membranesdrug deliverymetal‐organic frameworks

Identifiers

PMID41818608
PMCPMC13073244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.